Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab ...
The FDA approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa (Keytruda Qlex) in combination with ...
The Food and Drug Administration approved a combination treatment by Merck & Co., Pfizer, and Astellas Pharma for a hard-to-treat form of bladder cancer. The agency greenlit Merck's Keytruda and its ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. The Food and Drug Administration (FDA) has ...
Bladder cancer continues to be one of the most frequently diagnosed malignancies worldwide, with current treatments such as surgery and chemotherapy often ...
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient ...
The devastating diagnosis also turned out to be his first productive step toward negotiating a disease he had long feared ...
Rapid developments in muscle-invasive bladder cancer treatment are leading to new approaches to bladder preservation.
Bladder cancer remains one of the most frequently diagnosed urologic malignancies worldwide, imposing a heavy and persistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results